![glp 1 agonists for type 2 diabetes GLP-1-based therapies diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome glp-1_analogs [TUSOM | Pharmwiki]](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13098-025-01623-w/MediaObjects/13098_2025_1623_Figa_HTML.png)
glp 1 agonists for type 2 diabetes GLP-1-based therapies diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome glp-1_analogs [TUSOM | Pharmwiki]
Description
The numbers tell the story
![glp 1 agonists for type 2 diabetes GLP-1-based therapies diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
While medications that target GLP-1 can be life-changing for some people, others are looking for approaches that feel more sustainable, supportive, or aligned with long-term health goals
![glp 1 agonists for type 2 diabetes GLP-1-based therapies diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome glp-1_analogs [TUSOM | Pharmwiki]](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c31/8085572/9f34e4e391bd/gr6.jpg)
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: post hoc analyses from DECLARE-TIMI 58
![glp 1 agonists for type 2 diabetes GLP-1-based therapies diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome glp-1_analogs [TUSOM | Pharmwiki]](https://images.ctfassets.net/4f3rgqwzdznj/2zOOXVnmS5ExpkOMLBGlOZ/9626d72ba81ecfb39b173a74b699ced2/23-02_Comparison_of_GLP-1_Agonist_Drugs.png)
Although medications alone can help reduce the number on the scale, this four-level approach to obesity care management is integral to long-term success
![glp 1 agonists for type 2 diabetes GLP-1-based therapies diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome glp-1_analogs [TUSOM | Pharmwiki]](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3769457999954814822)
European Medicines Agency .Summary of product characteristics: OZEMPIC (semaglutide)
![glp 1 agonists for type 2 diabetes GLP-1-based therapies diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome glp-1_analogs [TUSOM | Pharmwiki]](https://www.freece.com/wp-content/uploads/2025/08/AdobeStock_642751321-1024x683.jpeg)
